口服轮状病毒活疫苗罗特威研究进展  

Progress of oral rotavirus(live) vaccine

作　　者：谢澎[1] 李青[1] 庞兴[1] 付敏强[1] 魏至栋[1] 

机构地区：[1]兰州生物制品研究所有限责任公司,兰州730046

出　　处：《中国新药杂志》2012年第10期1107-1109,1174,共4页Chinese Journal of New Drugs

摘　　要：轮状病毒是引起婴幼儿重症腹泻的最主要病原体,是全球范围内导致婴幼儿发病和死亡的主要病因之一。我国5岁以下婴幼儿轮状病毒腹泻发病人数每年超过1 000万,每年导致大约3～4万名婴幼儿死亡。接种安全有效的疫苗是预防轮状病毒腹泻的主要手段。口服轮状病毒活疫苗罗特威于2001年获准上市,累计接种已超过3 000万剂,安全有效,可有效降低轮状病毒腹泻的发病率。Rotavirus is the most common cause of severe diarrhea disease in infants and young children worldwide, and its infection has a major global impact on childhood morbidity and mortality. Rotavirus can cause an annual morbidity of more than 10 million diarrhea in children under the age of five in China, of which almost 30 000 to 40 000 children die. Safe and effective vaccination is the principal means to prevent diarrhea caused by rotaviruses. Oral rotavirus （live） vaccine has been approved for human use in 2001 and the sale has been accumulated to more than 30 million doses on the market. The result proved that it is safe and effective, and can effectively reduce the incidence of rotavirus diarrhea.

关 键 词：轮状病毒腹泻 轮状病毒疫苗 安全性 有效性 

分 类 号：R186[医药卫生—流行病学]